Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 607-617

  Prince, Stuart N ^a   Foulstone, Emily J ^a   Zaccheo, Oliver J ^a   Williams, Christopher ^a   Hassan, Andrew Bassim ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMODIMER; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MUTANT PROTEIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FIBROBLAST; GENE FUSION; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DROSOPHILA MELANOGASTER; EMBRYO; FIBROBLASTS; GENETIC VECTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KERATINOCYTES; LIGANDS; MICE; MICE, KNOCKOUT; PICHIA; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; RECEPTORS, FC; SURFACE PLASMON RESONANCE; THYMIDINE;

EID: 33847353816     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0509     Document Type: Article

References (76)

1. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
2. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005;205: 145-53.
3. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-95.
4. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
5. Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2003; 131:1187-94.
6. Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999;146:881-92.
7. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloprotei nase-7 facilitates Insulin-like growth factor bioavailability through its proteinase activity on Insulin-like growth factor binding protein 3. Cancer Res 2004; 64:665-71.
8. Hellawell GO, Turner GD, Davies DR, et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62: 2942-50.
9. Sell C, Rubini M, Rubin R, et al. Simian virus 40 large tumour antigen is unable to transform mouse embryonic fibroblasts lacking type I Insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-21.
10. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369:414-8.
11. Christofori G, Naik P, Hanahan D. Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during β-cell tumorigenesis. Nat Genet 1995;10:196-201.
12. Bates P, Fisher R, Ward A, et al. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995;72: 1189-93.
13. Haddad R, Held WA. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res 1997;57:4615-23.
14. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000;275:28341-4.
15. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307:1976-8.
16. Harper J, Burns JL, Foulstone EJ, et al. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 2006;66:1940-8.
17. Hassan AB, Howell JA. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 2000;60: 1070-6.
18. Sun Y, Gao D, Liu Y, et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006;25:1042-52.
19. Liao Y, Abel D, Grobholz R, et al. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005;36:1186-96.
20. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402.
21. Lu L, Katsaros D, Wiley A, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-α expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006; 12:1208-14.
22. Breuhahn K, Vreden S, Haddad R, et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004;64: 6058-64.
23. Miyamoto S, Nakamura M, Shitara K, et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 2005; 11:3494-502.
24. El-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-31.
25. Zhan S, Shapiro DN, Heiman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995; 11:2503-7.
26. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J. Natl Cancer Inst 2001;93:1698-703.
27. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.
28. Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2 and MEST lung adenocarcinoma. Mol Carcinog 2001;31:184-91.
29. Jirtle RL. IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer. Gastroenterology 2004; 126: 1190-201.
30. Daughaday WH, Trivedi B, Baxter RC. Serum "big insulin-like growth factor L" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. Proc Natl Acad Sci U S A 1993;90:5823-7.
31. Scott CD, Firth SM. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm Metab Res 2004;36: 261-71.
32. Hassan AB. Keys to the hidden treasures of the mannose 6-phosphate/ insulin-like growth factor 2 receptor. Am J Pathol 2003;162: 3-6.
33. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003;4:202-12.
34. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/ insulin-like growth factor type II receptor. Proc Natl Aced Sci U S A 1991;88:580-4.
35. Devi GR, Byrd JC, Slentz DH, MacDonald RG. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor. Mol Endocrinol 1998;12:1661-72.
36. Linnell J, Groeger G, Hassan AB. Real time kinetics of insulin-like growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor: the effects of domain 13 and pH. J Biol Chem 2001;276: 23986-91.
37. DaCosta SA, Schumaker LM, Ellis MJ. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia 2000;5: 85-94.
38. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.
39. Hankins GR, De Souza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996;12:2003-9.
40. Jamieson TA, Brizel DM, Killian JK, et al. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer 2003;3:4.
41. Olson LJ, Yammani RD, Dahms NM, Kim JJ. Structure of uPAR, plasminogen, and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor. EMBO J 2004;23:2019-28.
42. Brown J, Esnouf RM, Jones MA, et al. Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J 2002; 21:1054-62.
43. Roberts DL, Weix DJ, Dahms NM, Kim JJ. Molecular basis of lysosomal enzyme recognition: three-dimensional structure of the cation-dependent mannose 6-phosphate receptor. Cell 1998;93:639-48.
44. Zaccheo OJ, Prince SN, Miller DM, et al. Kinetics of insulin-like growth factor II (IGF-II) interaction with domain II of the human IGF-II/ mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues. J Mol Biol 2006;359:403-21.
45. Wu AM, Tan GJ, Sherman MA, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001;14:1025-33.
46. Hollister J, Conradt H, Jarvis DL. Evidence for a sialic acid salvaging pathway in lepidopteran insect cells. Glycobiology 2003;13:487-95.
47. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963;17:299-313.
48. Kim HJ, Kim TY. IGIF-II-mediated COX-2 gene expression in human keratinocytes through extracellular signal-regulated kinase pathway. J Invest Dermatol 2004;123:547-55.
49. Barreca A, De Luca M, Del Monte P, et al. In vitro paracrine regulation of human keratinocyte growth by fibroblast-derived insulin-like growth factors. J Cell Physiol 1992;151:262-8.
50. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990;345:78-80.
51. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anticarcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622-31.
52. Fang Y, Zhu Z, Xiao X, et al. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Their 2006;5:114-20.
53. Komesli S, Vivien D, Dutartre P. Chimeric extracellular domain type II transforming growth factor (TGF)-β receptor fused to the Fc region of human immunoglobulin as a TGF-β antagonist. Eur J Biochem 1998; 254: 505-13.
54. Forsten KE, Lauffenburger DA. Interrupting autocrine ligand-receptor binding: comparison between receptor blockers and ligand decoys. Biophys J 1992;63:857-61.
55. Forsten KE, Lauffenburger DA. Autocrine ligand binding to cell receptors. Mathematical analysis of competition by solution "decoys." Biophys J 1992;61:518-29.
56. Forbes BE, Hartfield PJ, McNeil KA, et al. Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis. Eur J Biochem 2002;269: 961-8.
57. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173:5343-8.
58. Duan DS, Werner S, Williams LT. A naturally occurring secreted form of fibroblast growth factor (FGF) receptor 1 binds basic FGF in preference over acidic FGF. J Biol Chem 1992;267:16076-80.
59. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain, and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
60. Asano Y, Yokoyama T, Shibata S, et al. Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. Cancer Res 1997;57:3395-7.
61. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405: 354-60.
62. Pitti AM, Marsters SA, Lawrence PA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396: 699-703.
63. Brantley DM, Chang N, Thompson EJ, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21: 7011-26.
64. Peters K, Werner S, Liao X, et al. Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. EMBO J 1994;13:3296-301.
65. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
66. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-9.
67. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Aced Sci U S A 2002;99: 11393-8.
68. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004;10:3327-32.
69. Scott CD, Ballesteros M, Madrid J, Baxter RC. Soluble insulin-like growth factor-II/mannose 6-P receptor inhibits deoxyribonucleic acid synthesis in cultured rat hepatocytes. Endocrinology 1996;137:873-8.
70. Scott CD, Weiss J. Soluble insulin-like growth factor II/mannose 6-phosphate receptor inhibits DNA synthesis in insulin-like growth factor II sensitive cells. J Cell Physiol 2000;182:62-8.
71. Lee JS, Weiss J, Martin JL, Scott CD. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 2003;107:564-70.
72. O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 2002;143:4287-94.
73. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996;56:4013-20.
74. Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003;14:669-82.
75. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor 1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumours. Cancer Cell 2004;5:221-30.
76. Gacia-Echevrria C, Pearson M, Marti A, et al. In vivo antitumour activity of NVP-AEW41 - a novel, potent, and selective inhibitor of the IGF-1R kinase. Cancer Cell 2004;5:231-9.